Workflow
Chronic cough treatment (implied by phase III trials)
icon
Search documents
Trevi Therapeutics targets multiple phase III trial launches for chronic cough indications in 2026 as regulatory plans accelerate (NASDAQ:TRVI)
Seeking Alpha· 2025-11-14 02:22
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...